Product Description
iTeos investigational A2Areceptor antagonist; iTeos lead therapeutic candidate, EOS100850, is a non-brain penetrant A2A receptor antagonist that retains high potency in the presence of elevated adenosine concentrations such as those measured in the tumor microenvironment. (Sourced from: https://investors.iteostherapeutics.com/news-releases/news-release-details/iteos-therapeutics-announces-collaboration-merck-investigating)
Mechanisms of Action: ADORA2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: iTeos Therapeutics
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Detheux
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Czech Republic, France, Germany, Italy, Korea, Spain, United Kingdom, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| A2A-005 | P2 |
Not yet recruiting |
Non-Small-Cell Lung Cancer |
2027-04-18 |
|
| A2A-005 | P2 |
Recruiting |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2025-04-01 |
|
| 2021-005487-22 | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2024-05-29 |
|
| IO-001 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2024-05-28 |